SML2217
Parecoxib sodium
≥98% (HPLC)
동의어(들):
SC-69124, Sodium (4-(5-methyl-3-phenylisoxazol-4-yl)phenylsulfonyl)(propionyl)amide
조직 및 계약 가격을 보려면 로그인를 클릭합니다.
크기 선택
제품정보 (DICE 배송 시 비용 별도)
실험식(Hill 표기법):
C19H17N2O4S · Na
CAS 번호:
Molecular Weight:
392.40
NACRES:
NA.77
UNSPSC Code:
51111800
Assay:
≥98% (HPLC)
Form:
powder
Storage condition:
desiccated
InChI
1S/C19H18N2O4S.Na/c1-3-17(22)21-26(23,24)16-11-9-14(10-12-16)18-13(2)25-20-19(18)15-7-5-4-6-8-15;/h4-12H,3H2,1-2H3,(H,21,22);/q;+1/p-1
InChI key
HQPVVKXJNZEAFW-UHFFFAOYSA-M
SMILES string
CC1=C(C2=CC=C(S([N-]C(CC)=O)(=O)=O)C=C2)C(C3=CC=CC=C3)=NO1.[Na+]
assay
≥98% (HPLC)
form
powder
storage condition
desiccated
color
white to beige
solubility
H2O: 2 mg/mL, clear
storage temp.
2-8°C
Biochem/physiol Actions
Parecoxib sodium is a non-steroidal anti-inflammatory drug (NSAID), a cyclooxygenase-2 (COX-2) selective inhibitor. It is a water-soluble and injectable prodrug of valdecoxib.
Non-steroidal anti-inflammatory drug (NSAID), a cyclooxygenase-2 (COX-2) selective inhibitor
signalword
Warning
hcodes
Hazard Classifications
Repr. 2
저장 등급
11 - Combustible Solids
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
F Camu et al.
Acta anaesthesiologica Scandinavica, 61(1), 99-110 (2016-12-03)
This study assessed non-inferiority of parecoxib vs. combination parecoxib+propacetamol and compared the opioid-sparing effects of parecoxib, propacetamol, and parecoxib+propacetamol vs. placebo after total hip arthroplasty. In this randomized, placebo-controlled, parallel-group, non-inferiority study, patients received one of four IV treatments after
Efrain Diaz-Borjon et al.
Pain and therapy, 6(1), 61-72 (2017-03-04)
Orthopedic surgeries are among the most common and most painful surgeries performed. A multimodal analgesic approach is recommended to reduce opioid consumption, provide effective pain relief, and improve outcomes following surgery. This study examined the efficacy and opioid-sparing effects of
Chang Liu et al.
Biochemical pharmacology, 138, 205-215 (2017-06-24)
One central factor in hepatopulmonary syndrome (HPS) pathogenesis is intravascular accumulation of activated macrophages in small pulmonary arteries. However, molecular mechanism underlying the macrophage accumulation in HPS is unknown. In this study, we aimed to explore whether elevated COX-2 induces
자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..
고객지원팀으로 연락바랍니다.